Abstract
No public abstract is available from the verified source records.
Abdelbari Baitar, Machteld De Vos, A. Vandebroek, Dirk L. A. L. Schrijvers
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
openalex
Confidence 95%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium
10.1002/1097-0142(19891215)64:12<2448::aid-cncr2820641209>3.0.co;2-7 · 1989
A prospective randomised trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumours
10.1200/jco.1990.8.6.1050 · 1990
A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study
10.1200/jco.1992.10.7.1066 · 1992
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large randomised, multinational, multicenter, phase III study
10.1200/jco.2000.18.17.3068 · 2000
10.1200/jco.2001.19.10.2638
10.1200/jco.2001.19.10.2638 · 2001
Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
10.1200/jco.1989.7.11.1748 · 1989
Prediction of creatinine clearance from serum creatinine
10.1159/000180580 · 1976
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
10.1016/j.ejca.2008.10.026 · 2009
Optimal two-stage designs for phase II clinical trials
10.1016/0197-2456(89)90015-9 · 1989
Carboplatin–gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function
10.1159/000012132 · 2000
Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: Effective treatment of patients with poor prognostic features
10.1023/a:1011186104428 · 2001
A feasibility study of carboplatin with fixed dose of gemcitabine in “unfit” patients with advanced bladder cancer
10.1016/s0959-8049(01)00295-7 · 2001
Our experience with 23 consecutive patients on gemcitabine/carboplatin chemotherapy for treatment of metastasized transitional cell carcinoma of the urothelium
10.1111/j.0919-8172.2004.00846.x · 2004
Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract
2003
Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group
10.1016/j.urology.2004.04.024 · 2004
A phase II trial of gemcitabine and carboplatin (GC) in patients with transitional cell carcinoma of the urinary tract (TCC)
10.1200/jco.2004.22.14_suppl.4590 · 2004
The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A phase II study of the Hellenic Cooperative Oncology Group
10.1002/cncr.21604 · 2006
A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urothelium
10.1186/1471-2407-7-98 · 2007
Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer “unfit” for cisplatin-based chemotherapy: Phase II results of EORTC study 30986
10.1200/jco.2008.21.4924 · 2009
Randomized phase II/III trial comparing gemcitabine/carboplatin (GC) and methotrexate/carboplatin/vinblastine (M-CAVI) in patients (pts) with advanced urothelial cancer (UC) unfit for cisplatin-based chemotherapy: Phase III results of EORTC study 30986
10.1200/jco.2010.28.18_suppl.lba4519 · 2010
No additional external references are available.